Insulin versus oral agents in the management of Cystic Fibrosis Related Diabetes: a case based study
<p>Abstract</p> <p>Background</p> <p>Insulin is the recommend therapeutic agent of choice for the management of Cystic Fibrosis Related Diabetes (CFRD), despite only sub-optimal reductions in glycemic control and increased morbidity and mortality reported by centers usi...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2006-06-01
|
| Series: | BMC Endocrine Disorders |
| Online Access: | http://www.biomedcentral.com/1472-6823/6/4 |
| _version_ | 1818641874347360256 |
|---|---|
| author | Langdon Leora J Onady Gary M |
| author_facet | Langdon Leora J Onady Gary M |
| author_sort | Langdon Leora J |
| collection | DOAJ |
| description | <p>Abstract</p> <p>Background</p> <p>Insulin is the recommend therapeutic agent of choice for the management of Cystic Fibrosis Related Diabetes (CFRD), despite only sub-optimal reductions in glycemic control and increased morbidity and mortality reported by centers using this agent. The newer insulin sensitizing agents demonstrated to have anti-inflammatory mechanisms may provide an alternative management option for CFRD.</p> <p>Methods</p> <p>A prospective case based therapeutic comparison between insulin, sulfonylurea, metformin and thiazolidinedione was observed over one decade with 20 CFRD patients diagnosed using American Diabetes Association guideline standards. Patients entering the study elected treatment based on risk and benefit information provided for treatment options. Patients receiving organ transplant or requiring combination diabetic medications were excluded from the study.</p> <p>Results</p> <p>No statistical advantage was achieved regarding overall glycemic control for oral agents over insulin. Additional outcome measures including changes in weight, liver function testing and FEV<sub>1 </sub>were not statistically significant.</p> <p>Conclusion</p> <p>Insulin alone may not be the only therapeutic option in managing CFRD. Oral hypoglycemic agents were equally effective in treating CFRD and may provide an alternative class of agents for patients reluctant in using insulin.</p> |
| first_indexed | 2024-12-16T23:34:06Z |
| format | Article |
| id | doaj.art-fb15c7da2bc44c0084603fddbf5d8cfa |
| institution | Directory Open Access Journal |
| issn | 1472-6823 |
| language | English |
| last_indexed | 2024-12-16T23:34:06Z |
| publishDate | 2006-06-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Endocrine Disorders |
| spelling | doaj.art-fb15c7da2bc44c0084603fddbf5d8cfa2022-12-21T22:11:48ZengBMCBMC Endocrine Disorders1472-68232006-06-0161410.1186/1472-6823-6-4Insulin versus oral agents in the management of Cystic Fibrosis Related Diabetes: a case based studyLangdon Leora JOnady Gary M<p>Abstract</p> <p>Background</p> <p>Insulin is the recommend therapeutic agent of choice for the management of Cystic Fibrosis Related Diabetes (CFRD), despite only sub-optimal reductions in glycemic control and increased morbidity and mortality reported by centers using this agent. The newer insulin sensitizing agents demonstrated to have anti-inflammatory mechanisms may provide an alternative management option for CFRD.</p> <p>Methods</p> <p>A prospective case based therapeutic comparison between insulin, sulfonylurea, metformin and thiazolidinedione was observed over one decade with 20 CFRD patients diagnosed using American Diabetes Association guideline standards. Patients entering the study elected treatment based on risk and benefit information provided for treatment options. Patients receiving organ transplant or requiring combination diabetic medications were excluded from the study.</p> <p>Results</p> <p>No statistical advantage was achieved regarding overall glycemic control for oral agents over insulin. Additional outcome measures including changes in weight, liver function testing and FEV<sub>1 </sub>were not statistically significant.</p> <p>Conclusion</p> <p>Insulin alone may not be the only therapeutic option in managing CFRD. Oral hypoglycemic agents were equally effective in treating CFRD and may provide an alternative class of agents for patients reluctant in using insulin.</p>http://www.biomedcentral.com/1472-6823/6/4 |
| spellingShingle | Langdon Leora J Onady Gary M Insulin versus oral agents in the management of Cystic Fibrosis Related Diabetes: a case based study BMC Endocrine Disorders |
| title | Insulin versus oral agents in the management of Cystic Fibrosis Related Diabetes: a case based study |
| title_full | Insulin versus oral agents in the management of Cystic Fibrosis Related Diabetes: a case based study |
| title_fullStr | Insulin versus oral agents in the management of Cystic Fibrosis Related Diabetes: a case based study |
| title_full_unstemmed | Insulin versus oral agents in the management of Cystic Fibrosis Related Diabetes: a case based study |
| title_short | Insulin versus oral agents in the management of Cystic Fibrosis Related Diabetes: a case based study |
| title_sort | insulin versus oral agents in the management of cystic fibrosis related diabetes a case based study |
| url | http://www.biomedcentral.com/1472-6823/6/4 |
| work_keys_str_mv | AT langdonleoraj insulinversusoralagentsinthemanagementofcysticfibrosisrelateddiabetesacasebasedstudy AT onadygarym insulinversusoralagentsinthemanagementofcysticfibrosisrelateddiabetesacasebasedstudy |